US clinical-stage biotech Immunome (Nasdaq: IMNM) saw its shares close up 37% at $23.11, after it announced a deal to acquire rights to an investigational Phase III drug for desmoid tumors.
Immunome yesterday disclosed it has entered into a definitive asset purchase agreement with Ayala Pharmaceuticals (OTCQX: ADXS) to acquire the latter’s AL102 and related drug candidate AL101. Ayala’s shares leapt 40% to $1.31yesterday, but were down more than 15% at $1.12 pre-market today.
Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash and $30 million in Immunome common stock (valued at 30-day VWAP as of February 1, 2024) at the closing and will pay up to an additional $37.5 million in development and commercial milestone payments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze